Chen et al., 2024

What It Targets Our GHK-Cu topical peptide is designed to target: Fine lines (crows feet, smile lines) and early wrinkles needing gentle, consistent softening. Mild to moderate laxity, crepiness, and loss of firmness in the face, neck, or dcollet. Photodamagedull tone, uneven texture, mottled pigmentation, and residual sun spots. Posttreatment skin (microneedling, peels, laser) that needs accelerated repair and reduced downtime. Benefits Topical GHK-Cu is believed to help with: Collagen + elastin boost: GHKCu cream has been shown to increase collagen I and III, dermal thickness, and elasticity, with clinical trials reporting up to ~3055% reductions in wrinkle volume and meaningful improvements versus retinoic acid or vitamin C in some studies. Barrier repair and calming: Copper peptides help restore barrier proteins and lipids, reducing redness, irritation, and dehydration while protecting skin from oxidative and inflammatory damage. Texture and tone refinement: Regular use smooths rough patches, softens acne marks, and helps lighten mottled hyperpigmentation and sun damage for a more even, luminous tone. Postprocedure friendly: Compared with many acids or strong retinoids, GHKCu is better tolerated and frequently used to speed healing and results after microneedling, laser, and RF, making it a perfect Better Med Spa addon.

Paliwal HP, et al
Cagrilintide Starting Dose and Titration Unlike tirzepatide's gradual multi-step escalation, cagrilintide trials have typically employed a simpler titration approach: Typical Cagrilintide Escalation: Weeks 1-4: 0.6 mg weekly Weeks 5-8: 1.2 mg weekly Week 9 onward: 2.4 mg weekly (maintenance) This three-step approach allows for tolerance development while reaching the therapeutic dose more quickly than tirzepatide's six-step protocol
Across 809 participants with a mean starting weight of 114.2 kg, CagriSema produced 23.0 per cent weight loss when all patients adhered to treatment, against 25.5 per cent for tirzepatide
All clinical context comes from compound-level research